Media ReleaseCOPENHAGEN, Denmark; February 19, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45th Annual TD Cowen Health Care Conference in Boston, Massachusetts at 1:50 PM EST (7:50 PM CET) on March 3, 2025.?A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-presentations.

Read more from the original source:
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste

Follow this link:
Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology

Leading clinician and researcher in Pulmonary Disease Therapeutics Leading clinician and researcher in Pulmonary Disease Therapeutics

See the original post here:
OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors

SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025.

Here is the original post:
NAYA Biosciences Announces Nomination of New Board Members

BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) for development and commercialization of RB-164 (SYS6005): a novel clinical stage antibody drug conjugate (ADC) targeting ROR-1. The agreement covers exclusive commercialization rights to RB-164 in the United States of America (USA), Canada, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, and Australia. CSPC will retain all rights to SYS6005 in the remaining global markets.

View original post here:
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

Read more here:
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress.

View original post here:
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange (“TSXV”). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone’s leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone’s strong market performance and strategic advances in the past year including 110% share price appreciation and 209% market cap growth.

Read the original here:
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock

This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry

Excerpt from:
COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

TAMPA, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, announced today that it convened its special meeting (“Special Meeting”) and immediately adjourned the meeting, with conducting any business, to March 21, 2025. The Special Meeting was adjourned as to all of the proposals contained in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on January 28, 2025 (the “Proxy Statement”), including the proposal to approve the arrangement transaction with SRx Health Solutions, Inc. (“SRx”).   The Company adjourned the Special Meeting to allow SRx to continue to pursue its shareholder vote and the final order by the Ontario Superior Court of Justice required to consummate the arrangement transaction and to update Better Choice shareholders of certain corporate actions to be taken by SRx and the Company to ensure compliance with the NYSE American listing requirements.

Go here to see the original:
Better Choice Company Adjourns Special Meeting of Stockholders to March 21, 2025

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA.

Read more here:
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

GRI’s common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025

Visit link:
GRI Bio Announces Reverse Stock Split

Company announcement – No. 2 / 2025

Here is the original post:
Zealand Pharma Announces Financial Results for the Full Year 2024

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Continue reading here:
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows:

Originally posted here:
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025.

Originally posted here:
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance - as part of the InnoBio investment strategy.

Original post:
EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform...

February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.

Read more:
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025

WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments.

Go here to see the original:
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

CITRYLL DEMONSTRATES A BROADER THERAPEUTIC POTENTIAL FOR CIT-013 IN THE TREATMENT OF INFLAMMATORY DISORDERS

Go here to see the original:
Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders